- Home
- NMRA
as 06-20-2025 3:39pm EST
Stocks
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 121.0M | IPO Year: | 2023 |
| Target Price: | $9.29 | AVG Volume (30 days): | 820.4K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $17.19 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Neumora Therapeutics Inc. News
NMRA Breaking Stock News: Dive into NMRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M
GuruFocus.com
a month ago
Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...
GlobeNewswire
a month ago
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
a month ago
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?
GlobeNewswire
2 months ago
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BioPharma Dive
2 months ago
Former Neumora CEO to lead Galapagos spinout
MT Newswires
3 months ago
William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform
Zacks
3 months ago
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Compare NMRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NMRA Neumora Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.